Abstract-Nephroblastoma overexpressed (NOV) is a member of the CCN family (connective tissue growth factor, CYR61, and NOV) of proteins that are involved in regulating the proliferation, differentiation, and adhesion of a variety of cell types. We have examined the expression of the Nov gene and NOV protein by vascular smooth muscle cells (VSMCs), in vitro and in vivo, and the effects of recombinant NOV on VSMCs. Rat aortic VSMCs were found to express Nov mRNA and NOV protein in vitro and in vivo. Nov expression in adult rat tissues was very high in the aorta and was detected only weakly in the brain and lung by Northern analysis (relative levels 33:3:1). During postnatal development (3 days to 12 weeks), the expression of Nov was correlated with markers of the differentiated smooth muscle cell phenotype (smooth muscle myosin heavy chain and SM22␣). In the rat carotid artery balloon injury model, Nov was detectable by in situ hybridization and was downregulated in the media of the injured artery compared with the uninjured artery at 7 and 14 days after injury. Expression in the developing intima was barely detectable at 7 days after injury except for strong expression at the luminal surface. At 14 days after injury, Nov expression was substantially increased throughout the intima. In vitro studies of the function of NOV protein showed that it promoted VSMC adhesion via a mechanism that was divalent cation and Arg-Gly-Asp independent but that it did not modulate VSMC proliferation or phenotype. The strong expression and dynamic regulation of Nov in the arterial wall, together with its ability to promote VSMC adhesion, suggest that it may be involved in homeostasis and repair. (Arterioscler Thromb Vasc
I
n experiments designed to screen for basic helix-loop-helix transcription factors potentially involved in controlling vascular smooth muscle cell (VSMC) phenotype, we obtained a set of known factors, including Dermo-1 and Twist. 1, 2 A number of other clones were also isolated, and among those identified was the Nov gene. 3 Nov does not encode a transcription factor but encodes a member of the CCN family of growth regulators (for a recent review, see Reference 4) . Prototypical members of the CCN family (cysteine-rich [CYR61], connective tissue growth factor [CTGF] , and nephroblastoma overexpressed [NOV] ) are characterized by a high degree of sequence homology that includes complete conservation of 38 cysteine residues. 5 Analysis of each protein revealed 4 distinct protein modules: an insulin-like growth factor binding domain, a von Willebrand factor type C repeat, a thrombospondin type 1 repeat, and a C-terminal module. 5 In addition, each of the proteins possesses an amino-terminal signal peptide, indicating that they are secreted proteins.
CYR61 and CTGF are the most extensively studied members of the CCN family. Both proteins have been shown to associate with the extracellular matrix, and the recombinant proteins regulate a diverse array of cellular activities, including adhesion, 6 -10 migration, 6, 8, 9, 11 proliferation, 8, 9, 11, 12 differentiation, 13 survival, 6 matrix gene expression, 14, 15 and angiogenesis. 6, 11, 16 From their expression patterns in development and disease, it has been suggested that CYR61 and CTGF are involved in the regulation of chondrogenesis 8, 13 and wound repair 17 and in the pathogenesis of cancers 15, 18 and fibrotic 19 -21 and vascular diseases. 22 In contrast to the association of CYR61 and CTGF with tumorigenesis, 2 new members of the CCN family, ELM-1 (expressed in low metastatic type 1 cells) and COP-1, are suggested to inhibit tumorigenesis. 23, 24 Relatively little is known about the function of NOV. [3] [4] [5] However, NOV is potentially of interest in relation to vascular disease because the data suggest that it is an inhibitor of cell proliferation, first demonstrated for chick embryo fibroblasts (CEFs) grown in soft agar. 3 Furthermore, it has been shown that Nov is downregulated in CEFs transformed by tsp60
v-src and in proliferating untransformed cells stimulated by serum or phorbol ester. 25 These observations prompted us to determine whether expression of the gene was correlated with the differentiated nonproliferating VSMC phenotype in vitro and in vivo. We compared the amount of Nov in RNA extracted from intact rat aortas at different stages of postnatal development with the differentiated status of the VSMCs defined by the expression of smooth muscle myosin heavy chain (SM-MHC) and SM22␣ genes. In the rat carotid balloon injury model, significant VSMC migration, proliferation, and dedifferentiation occur in response to arterial injury. 26 -28 Therefore, we compared the expression of Nov in the media of the uninjured carotid artery with the expression of Nov in the media and intima of the injured artery. The effect of recombinant NOV protein on the proliferation, differentiation, and adhesion of VSMCs was also determined.
Methods

Cell Culture
Rat aortic VSMCs from adult (12-week-old) Wistar rats, derived previously as described, 44 were maintained in DMEM supplemented with 10% (vol/vol) FCS.
Proteins, Peptides, and NOV Antibody
NOV antibody was raised by immunizing rabbits with synthetic peptides corresponding to the 21 C-terminal residues (334 to 354) of mouse NOV. This region bears little sequence homology to other CCN family proteins. The NOV antibody did not cross-react with recombinant CYR61 or CTGF, CCN proteins previously shown to be expressed by VSMCs (References 9 and 22, data not shown). IgG fractions were prepared from crude serum samples by using a commercial IgG purification kit (Pierce) and following the manufacturer's instructions. Rat platelet-derived growth factor and human basic fibroblast growth factor were from R & D systems. Vitronectin was from Sigma Chemical Co. GRGDS and GRGES peptides were purchased from Bachem.
Reverse Transcription-PCR and Cloning
Reverse transcription was performed on total RNA isolated from cultured rat aortic VSMCs as described. 40 Degenerate primed PCR was performed in a 50-L PCR reaction containing 5 L cDNA, Taq reaction buffer, 200 mol/L dNTPs, 125 pmol primer A [CGC (A/C/T)TT (C/T)CG NGA (A/G)CT (A/C/G)CG, corresponding to amino acids 113 to 118 (AFAELR) of Thing-1, now known as eHAND 45 ], 125 pmol primer B [(A/G)TA NC(A/T) NGT NGC (C/G)AG (C/G/T)G(G/T) (C/G)AG, reverse and complement of the sequence corresponding to amino acids 136 to 142 (LRLATSY) of eHAND 45 ], and 2.5 U Taq polymerase. Reactions were performed by using 35 cycles of 1 minute at 95°C, 1 minute at 52°C, and 1 minute at 72°C. Amplification products of Ϸ90 bp were purified and cloned into pCRII (Invitrogen). Clones were sequenced by use of T7 polymerase (Pharmacia) or automatically on an ABI 373 sequencer.
PCR amplification of Nov coding sequences was performed as described above by using 12.5 pmol upstream primer (CGAAAGC-GATGCCTCTGCCTAGGCTTC, nucleotides 42 to 74 of MMNOVR), 12.5 pmol downstream primer (GCACCTGTTA-AATTTCTCCTCTGCTTG, nucleotides 1104 to 1078 of MMNOVR), and an annealing temperature of 57°C. PCR products were cloned in the pGEM-T-Easy vector (Promega) and sequenced as described above.
Northern Blot Analysis
Total RNA was prepared from cell cultures and tissues by using the acid guanidinium thiocyanate-phenol-chloroform method. 46 RNA samples (10 g per lane) were subjected to Northern blot analysis as previously described. 47 The Nov cDNA probe that was used spanned the entire coding cDNA for Nov. SM-MHC, SM22␣, and ␤-actin cDNA probes have been described previously. 40 Lysates were clarified by centrifugation at 12 000g for 10 minutes at 4°C, pooled, and frozen at Ϫ85°C. After they were thawed, lysates and medium samples were divided into aliquot portions (800 L lysate and 2 mL medium), and each sample was precleared by incubation with 25 L of protein A-agarose (Sigma) for 1 hour at 4°C. Samples were incubated for 2 hours on ice with either 2.5 g/mL preimmune IgG or 2.5 g/mL relevant IgG in the presence or absence of 15 g/mL competing peptide used as the immunogen. Immune complexes were precipitated by incubating the samples with 25 L protein A-agarose for 2 hours at 4°C. Protein A beads were washed 4 times with ice-cold RIPA buffer, and bound proteins were solubilized in SDS-PAGE sample buffer. Protein samples were separated on 12% SDS-PAGE gels, which were incubated in fluorographic reagent (Amplify, Amersham), dried, and exposed to Fuji RX film at Ϫ85°C.
Western Blot Analysis
For the analysis of NOV protein, the aorta of a female adult Wistar rat was dissected, stripped of surrounding tissue, and snap-frozen in liquid nitrogen. After reducing the tissue to powder at Ϫ80°C, total protein was extracted into 500 L 2ϫ sample buffer (1ϫ sample buffer consists of 125 mmol/L Tris-HCl, pH 6.8, 10% [vol/vol] glycerol, 2% [wt/vol] SDS, 0.1 mg/mL bromophenol blue, and 2% [vol/vol] ␤-mercaptoethanol). Forty microliters of the protein extract (per lane) was separated on a 13% SDS-PAGE gel and blotted onto a PVDF membrane (Immobilon-P, Millipore). Blots were incubated overnight at 4°C in PBS containing 5% (wt/vol) nonfat milk, 0.1% (vol/vol) Tween 20, and either 0.4 g/mL preimmune IgG or 0.4 g/mL anti-NOV IgG in the absence or presence of 20 g/mL NOV blocking peptide. Blots were incubated with an anti-rabbit IgG conjugated to horseradish peroxidase, and immunoreactive bands were visualized by using the enhanced chemiluminescence detection system (Pierce) and following the manufacturer's recommendations.
For the analysis of SM-MHC expression, adult rat aortic VSMCs were isolated as described 44 and seeded into 24-well plates that had been coated with NOV (100 g/mL) overnight at 4°C or left uncoated. Cells were harvested after 0, 72, and 144 hours in primary culture in the presence of serum. Cells were trypsinized and counted before being lysed in 1ϫ sample buffer without bromophenol blue and ␤-mercaptoethanol. The protein concentration was determined by using the bicinchoninic acid method (Sigma). Total protein (2.5 g per lane) was separated onto a 4% to 12% SDS-PAGE gel (Novex) and analyzed by Western blotting as described above with use of an anti-SM-MHC polyclonal antibody (1:10 000 50 ).
Balloon Catheter Injury of the Rat Carotid Artery
Twelve-week-old female Wistar rats (nϭ6), weighing Ϸ300 g, were subjected to balloon catheter injury of the carotid artery according to the protocol of Brown et al. 51 Animals were euthanized either 7 days (nϭ3) or 14 days (nϭ3) after surgery by CO 2 asphyxiation, and the left and right common carotid arteries were excised. Loose surrounding tissue was carefully removed, and both arteries were immersed together in a 10-mL syringe filled with Cryo-M-Bed (Bright Instruments), snap-frozen in liquid nitrogen, and stored at Ϫ85°C.
In Situ Hybridization
Sense and antisense riboprobes were synthesized in the presence of [␣- 35 S]UTP (Ϸ1500 Ci/mmol, 20 mCi/mL; Amersham) from pBluescript vector containing bases 388 to 1004 of the Nov cDNA by using an in vitro transcription kit (Maxi-Script, Ambion). Sections (12 m) were cut, thaw-mounted onto microscope slides (SuperFrost Plus, BDH), and refrozen at Ϫ85°C. Sections were thawed into PBS containing 4% (wt/vol) paraformaldehyde for 30 minutes at room temperature. Section pretreatments, hybridization, and washing were carried out according to the method of Trezise et al. 52 Sections were exposed to autoradiographic emulsion (NK2B, Kodak) for 4 days at 4°C. After development, sections were stained with Harris' hematoxylin (Sigma) and mounted. Photomicrography was carried out by using a Nikon microscope (Eclipse E600) with Nikon photographic equipment (H-III).
Production and Purification of Recombinant NOV Protein
The entire open reading frame of the rat NOV cDNA was cloned into the baculovirus transfer vector, pBlueBac 4.5 (Invitrogen). A purified high-titer stock of recombinant NOV baculovirus (NovBac.4) was generated with use of the MaxBac 2.0 kit (Invitrogen) according to the manufacturer's instructions, except that Sf 9 cells were grown in SF900II medium, and BSA (Sigma) was added to 0.5% (wt/vol) for storage of the virus. Log-phase Sf 9 cells in shaker culture were infected with NovBac.4 at an approximate multiplicity of infection of 10. After 60 hours, the conditioned medium was harvested by centrifugation at 5000 rpm for 10 minutes at 4°C and further clarified by filtration through a 1.6-m glass-fiber filter (Millipore). The medium was adjusted to 10 mmol/L Tris-HCl, pH 7.0, and 1 mmol/L EDTA and applied to a 5-mL heparin-Sepharose column (Amersham-Pharmacia Biotech) at 2.5 mL/min at 4°C. The column was washed with 80 column volumes of buffer A (10 mmol/L Tris-HCl, pH 7.0, and 1 mmol/L EDTA) containing 0.15 mol/L NaCl, and bound proteins were eluted with a 50 mL linear NaCl gradient (0.15 to 1 mol/L in buffer A). Fractions containing partially purified NOV were gel-filtered with use of a Superdex-75 gel filtration column (Amersham-Pharmacia Biotech) equilibrated in buffer A containing 0.5 mol/L NaCl. The eluate was diluted at a ratio of 1:4 with buffer B (50 mmol/L MES-NaOH, pH 6.0, and 1 mmol/L EDTA) and applied to a 5-mL Sepharose-SP column (AmershamPharmacia Biotech) at 1 mL/min at 4°C. The column was washed with 5 column volumes of buffer B containing 0.1 mol/L NaCl, and bound proteins were eluted with a linear NaCl gradient (0.1 to 1 mol/L NaCl, in buffer B). Fractions containing purified NOV were pooled and dialyzed extensively against Dulbecco's PBS (GIBCO). The protein concentration was determined by using Bradford assay reagent (Sigma) with BSA as the protein standard. The protein was stored in 100 L aliquots at Ϫ20°C.
DNA Synthesis Assays
VSMCs were seeded into 24-well plates at 1.5ϫ10 4 cells per well and grown for 2 days. The cells were made quiescent by serum starvation for 48 hours and then stimulated with DMEM supplemented with platelet-derived growth factor (100 ng/mL), basic fibroblast growth factor (100 ng/mL), or serum (10% [vol/vol]) in the presence or absence of NOV (5 g/mL). Eighteen hours after stimulation [ 3 H]thymidine (5 Ci/mmol, Amersham Pharmacia) was added to 1 Ci/mL, and after a further 6 hours, cells were harvested, and incorporation of [ 3 H]thymidine was determined as described. 53 
Cell Adhesion
Immunologic microtiter wells (Maxi-Sorp, GIBCO) were coated in Dulbecco's PBS (GIBCO) containing protease-free BSA (Sigma), NOV (15 g/mL), or vitronectin (1 g/mL) for 16 to 20 hours at 4°C. Wells were blocked with PBS containing 1% (wt/vol) BSA for 1 hour at room temperature before the addition of cells. VSMCs were grown to confluence and then harvested by trypsinization. The cells were washed in DMEMϩ10% FCS, centrifuged, resuspended in serum-free DMEM, and adjusted to Ϸ3ϫ10 5 cells per milliliter. One hundred microliters of this suspension was added to each test well, and after incubation at 37°C for 1 hour, adhered cells were fixed in saline containing 4% (vol/vol) formaldehyde. Cells were stained with methylene blue and quantified by measuring the absorbance of the extracted dye at 650 nm. The absorbance of the extracted dye at 650 nm was directly proportional to the number of attached cells up to a plating density of 7.5ϫ10 4 cells per well (data not shown).
Results
Identification and Cloning of the Rat Nov Gene
Expression of the Nov gene in adult rat aortic VSMCs in vitro was detected as a 90-bp polymerase chain reaction (PCR) product amplified as part of a degenerate primed PCR screen for basic helix-loop-helix proteins by use of primers to the helix-loop-helix domain of eHAND (see Methods). To isolate the complete rat Nov coding sequence, primers (see Methods) based on the mouse and human Nov sequences were made, and a full coding sequence for Nov was amplified from rat aortic cDNA. The resultant PCR product was cloned into pTAG and sequenced. This sequence was 99.8% identical to that recently reported for rat Nov 29 (accession number AF171936). The nucleotide sequence of rat Nov was 91% and 79.4% homologous to mouse Nov and human Nov, respectively, and the corresponding predicted protein sequence was 92% and 81.1% homologous, respectively.
Nov Expression by Rat Aortic VSMCs in Culture
Previous studies have shown that Nov expression in CEF cells was increased when the cells became quiescent. 25 To determine whether Nov expression by VSMCs was affected by proliferation, RNA was extracted from proliferating and stationary-phase adult rat aortic VSMCs and analyzed by Northern blotting. Nov mRNA was detected as a major transcript of 2.5 kb and a minor transcript of Ϸ2.0 kb ( Figure  1a ). The level of Nov mRNA in adult rat aortic VSMCs in vitro was very similar in subconfluent proliferating cells and in the same cell cultures after the stationary phase was reached ( Figure 1a ; see Methods). However, withdrawal of serum from either cell culture for 24 hours resulted in a 2-to 3-fold increase in Nov expression (Figure 1a ). These observations suggest that Nov expression in rat aortic VSMCs is downregulated by growth factors and/or mitogens present in FCS irrespective of whether the cells are proliferating or not. The CCN proteins identified to date all contain a leader peptide and are secreted proteins. To determine whether rat aortic VSMCs synthesized and secreted NOV, cells were cultured in cysteine-and methionine-free medium that had been supplemented with 35 S-labeled cysteine and methionine. The cells and medium were harvested after 4 hours, and NOV was immunoprecipitated from both samples. NOV was detected as 2 forms that migrated at Ϸ46 kDa and 48 kDa in the cell lysates (Figure 1b ) and as at least 1 form of 48 kDa in the medium. These forms of NOV are larger than the predicted primary NOV translation product (40 kDa), and this difference in size is likely to reflect N-glycosylation of the protein as previously described. 30 
Nov Expression In Vivo
Previous data have shown that Nov is expressed in a range of tissues in rats, humans, and chickens. 3, 29, 31 To determine whether vascular smooth muscle expressed Nov in vivo, RNA was isolated from a variety of adult rat tissues, and Nov expression was determined by Northern analysis. By far the strongest expression of Nov was in the aorta, and it was also detected weakly in the brain and lung (Figure 1c) . The relative amounts of Nov mRNA in the 3 tissues normalized to lung were 33:3:1, respectively. Western analysis of protein isolated from the rat aorta showed that the RNA was translated into protein. NOV was detected as a doublet of Ϸ46 to 48 kDa and an additional doublet of Ϸ28 to 30 kDa (Figure 1d ). The lower molecular mass forms of NOV are likely to reflect proteolysis of NOV at the hinge region of the protein, 5 as previously observed for insect cell-and mammalian cell-derived NOV. 32 In situ hybridization of a 35 S-labeled antisense Nov probe in rat aortic sections showed that Nov mRNA was highly expressed by the smooth muscle cells of the aorta (Figure 2a  through 2d ). Similar analysis of adult rat lung sections showed that Nov mRNA expression was also restricted to the smooth muscle cells of the lung (Figure 2e through 2h) .
Nov Expression in the Aorta During Postnatal Development
Experiments were performed to determine whether Nov expression was correlated with the differentiated status of rat aortic smooth muscle cells. Compared with adult aortic VSMCs, the VSMCs of the neonatal aorta have previously been shown to express less mRNA for several markers of the fully differentiated VSMC phenotype. 33 Nov expression was compared with the expression of SM-MHC and SM22␣ in RNA isolated from the aorta of 3-and 14-day-old neonatal rats and adult rats (Figure 3a) . Nov mRNA was detectable by Northern analysis in all 3 samples and was Ϸ10-fold higher in the aortas of the adult rats than in the aortas of the neonatal rats (Figure 3b ). These data show that Nov expression was correlated with the expression of VSMC differentiation markers during postnatal development. A similar correlation of Nov expression with markers of VSMC differentiation was observed in passaged rat aortic VSMCs that had dedifferentiated in vitro (Figure 3a and 3b) .
Expression of Nov in the Rat Carotid Injury Model
Dedifferentiated arterial VSMCs are generated in response to arterial injury. 27 For example, in the rat carotid injury model, VSMCs are the only type of cells that have been detected in the neointima and are dedifferentiated compared with the uninjured medial cells, as defined by their levels of smooth muscle-specific contractile proteins. 34, 35 Therefore, it was of interest to determine whether Nov expression was correlated with the differentiated phenotype of the VSMCs in this model. In situ hybridization showed that Nov was easily detectable and uniformly expressed in the uninjured left carotid artery at 7 and 14 days after injury of the right carotid artery and was similar to the expression of Nov in the aorta (Figure 4 ). At 7 days after balloon injury, Nov expression in the media of the injured carotid artery was substantially reduced, and expression was very low in the developing intima compared with the media of the uninjured artery except at the luminal edge of the intima, where expression was high. At 14 days after injury, expression of Nov in the media of the injured artery remained low but was substantially increased in the VSMCs throughout the intima.
Effects of NOV Protein on VSMCs In Vitro
Other members of the CCN family of proteins have been shown to modulate the growth, differentiation, and adhesion of a variety of cell types. To determine the function of NOV protein on arterial VSMCs, we generated purified recombinant NOV protein (Figure 5a ) by using the baculoviral expression system (see Methods). Addition of NOV to serum-starved VSMCs did not cause the cells to synthesize DNA in the absence of added mitogen nor did it affect serumor growth factor-stimulated DNA synthesis in the same cells (Figure 5b) . Furthermore, plating primary VSMCs onto NOV-coated wells also had no effect on the rate of cell proliferation (Figure 5c ).
VSMCs dispersed into primary culture dedifferentiate, as marked by the loss of expression of smooth muscle-specific proteins (eg, SM-MHC 36 ). To determine whether NOV affected the differentiation of VSMCs, primary cells were plated onto NOV-coated wells and cultured for 48, 96, or 144 hours. Western analysis of the SM-MHC content of these cells showed that the cells dedifferentiated whether they were plated onto NOV protein or onto untreated culture plastic (Figure 5d ). Similar analysis showed that the addition of soluble NOV protein to primary VSMCs also had no effect on the SM-MHC protein content of the cells (results not shown).
Taken together, these data indicate that NOV does not affect VSMC proliferation or differentiation, at least under these culture conditions. However, it was noted from these studies that the primary cells could adhere to NOV protein.
To analyze the adhesion of arterial VSMCs to NOV, immunologic microtiter plates were coated with NOV, vitronectin, or BSA. VSMCs were added to the wells and incubated for 60 minutes at 37°C. These experiments showed that VSMCs adhered to NOV or vitronectin but not to BSA (Figure 6a ). The adhesion of VSMCs to NOV, but not to vitronectin, was inhibited by preincubating the wells with the anti-NOV antibody before cell plating (Figure 6a) . The inhibitory action of the anti-NOV antibody was reversed if an excess of the C-terminal peptide was present (Figure 6a ). These data indicate that NOV can specifically promote VSMC adhesion and suggest the existence of a VSMC surface NOV receptor. CYR61 and CTGF have been shown to be ligands for the integrin receptor ␣ v ␤ 3 . 6, 10 To determine whether the adhesion of VSMCs to NOV occurred through an integrin-dependent mechanism, cell adhesion assays were performed in the presence of EDTA or the Arg-Gly-Asp (RGD)-containing peptide, GRGDS. Adhesion of VSMCs to vitronectin was abolished by the addition of 20 mmol/L EDTA or 0.5 mmol/L GRGDS but not by the control peptide GRGES (Figure 6b , and from 14-day-old and 3-day-old neonatal rat aortas (lanes 3 and 4, respectively) was analyzed by Northern blotting. The blot was probed with a 32 P-labeled Nov cDNA probe as described in Methods. The same blot was also probed by using SM-MHC, SM22␣, and ␤-actin cDNAs. b, Bar graph shows the relative levels of Nov, SM-MHC, and SM22␣ mRNAs from Northern blot analysis (shown in panel a) after normalizing against ␤-actin mRNA levels. Signal intensities were determined by ImageQuant software. and 6c). However, neither agent inhibited the adhesion of VSMCs to NOV (Figure 6b and 6c) . The C-terminal peptide of NOV also did not prevent VSMC adhesion to NOV (Figure 6b ). These data suggest that inhibition of VSMC adhesion to NOV by the NOV antibody is not due to direct interaction with the binding site for the NOV receptor but is presumably due to indirect steric effects. These data indicate that adhesion of VSMCs to NOV is independent of divalent metal ion-and RGD-binding sites, implying that adhesion is not integrin dependent.
Discussion
The striking observation described in the present study is the very high level of Nov mRNA expression in the rat aorta and carotid arteries, substantially higher (by at least an order of magnitude) than in the brain and lung tissues previously shown to express this gene. 29 Furthermore, Nov expression in the lung was also restricted to the smooth muscle components of the tissue. Very strong expression of Nov is limited to the aorta, which contrasts with expression of CTGF and CYR61, members of the CCN family that are strongly expressed in a wide range of tissues, 31, 37, 38 and therefore suggests a tissuespecific role for Nov in the arterial wall.
The high levels of arterial Nov mRNA expression are correlated with protein expression that is readily detectable by Western blot, and the protein is processed as described previously for NOV. 30 However, it was not possible to use the antibody to the C-terminal peptide of NOV for detection by immunofluorescence in the vessel wall because no staining could be detected in sections prepared under a variety of conditions. The native form of the protein was immunoprecipitated by the antibody after secretion from VSMCs in vitro; therefore, it is likely that the antigenic determinant is inaccessible in the arterial sections through interactions of the protein with components of the vessel wall, including VSMCs. The multidomain structure of the protein suggests that it is likely to bind to components of the matrix, including heparin-like oligomers. 5 The strong expression of Nov in the intact aorta and smooth muscle cells in the lung suggested that it might be a marker 5 cells per milliliter) were added to the wells, and the plates were incubated for 60 minutes at 37°C. Cells were washed 3 times with DMEM, fixed, and quantified with the use of methylene blue (see Methods). a, During the blocking step, some wells were incubated with BSA containing preimmune IgG (150 g/mL) or anti-NOV IgG (150 g/mL) in the absence or presence of a NOV-competing peptide (50 g/mL). b and c, Before they were plated, cells were preincubated for 15 minutes at room temperature in the presence of EDTA (20 mmol/L), GRGES (0.5 mmol/L), GRGDS (0.5 mmol/L), or a NOV-competing peptide (50 g/mL), which remained present throughout the assay. All assays were performed in triplicate in at least 3 different experiments. Data presented are meanϮSEM for a representative experiment. Adhesion of cells to VN varied up to 2-fold relative to NOV (compare panels b and c).
of the fully differentiated smooth muscle phenotype. Expression of Nov was correlated with the expression of genes for smooth muscle-specific contractile proteins in postnatal development and in VSMCs in vitro. Recent immunohistochemical studies have revealed that NOV protein expression is tightly associated with sites of heterotypic blastemal differentiation in Wilms' tumors 30 and that its accumulation in fully differentiated structures of the developing kidney and nervous system is consistent with a role in promoting mesenchymal cell differentiation. However, the data from the carotid balloon injury model suggest that Nov expression is not tightly coupled to the expression of smooth musclespecific contractile proteins in the complex changes in the vessel wall that occur after injury, including smooth muscle cell dedifferentiation. For example, the levels of SM-MHC and SM-␣-actin proteins are reduced in the intima compared with the media at 14 days after injury, 34 whereas the levels of Nov mRNA are increased. This conclusion is consistent with the data showing that although genes for smooth musclespecific contractile proteins have CArG elements in their promoters and are strongly regulated by serum response factor, 39 -42 no CArG elements in the Nov promoter have been identified. 43 The data also imply that NOV is unlikely to control smooth muscle phenotype, which is consistent with the inability of recombinant NOV protein to inhibit the dedifferentiation of primary VSMC cultures. It should be noted, however, that there are no data reported for mRNA levels for smooth muscle-specific contractile proteins in the carotid balloon injury model that enable direct comparison with the changes in Nov mRNA levels reported in the present study.
The data for expression of Nov in vivo and the analysis of the effects of NOV protein in vitro provide some insight into functions that NOV may exert in the arterial wall. The pattern of changes in Nov mRNA expression in response to injury and the ability of NOV to promote the adhesion of VSMCs in vitro are consistent with a role in regulating the migration of smooth muscle cells. For example, reduced Nov expression in the media might be involved in releasing VSMCs for migration and proliferation to form the intima, and reexpression of Nov may occur as the migration and proliferation slow down in the later stages of intimal development at day 14. It should also be noted that dedifferentiated proliferating VSMCs express Nov RNA and protein in vitro. Furthermore, the addition of NOV protein to cultured VSMCs did not affect the rate of proliferation in serum or DNA synthesis in response to serum or single mitogens. These data indicate that NOV is not an effective inhibitor of proliferation, at least in vitro. However, the expression of Nov RNA is enhanced when serum is withdrawn, consistent with the strong expression of Nov by quiescent VSMCs in the uninjured media.
Although the structure of NOV has yet to be determined, it is thought that the protein has a multidomain structure. The adhesion of VSMCs to NOV was inhibited by an antibody to the C-terminal 21 amino acids of NOV, suggesting that the cells adhere to the CT domain of the protein. The integrinindependent adhesion of VSMCs to NOV, as evidenced by the absence of inhibition by RGD peptide and EDTA, is in contrast to the adhesion of other cells to CYR61 and CTGF, which have been shown to bind to the integrins ␣ v ␤ 3 and ␣ iib ␤ 3 . 6,7,10 It remains possible that NOV can also bind to integrins but that binding is masked in our assays through the strong interaction of NOV with other receptors on the VSMC surface. The effects of CYR61 and CTGF on the adhesion of VSMCs have yet to be assayed to determine whether these proteins promote adhesion through an integrin-independent mechanism. Further analysis of the potential functions of NOV in vascular development and response to injury will be facilitated by the development in progress of mice in which the expression of Nov is genetically modified.
